Mirjam Fässler
BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors
Hasan Ali O, Sadik C, Zillikens D, Schmidt E, Jochum W, Mani B, Cozzio A, Braun A, Emtenani S, Hammers C, Abdou M, Diem S, Fässler M, Berner F, Ring S, Bomze D, Flatz L. BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. J Am Acad Dermatol 2019; 82:854-861.
Aug 23, 2019BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors
Aug 23, 2019J Am Acad Dermatol 2019; 82:854-861
Hasan Ali Omar, Sadik Christian D, Zillikens Detlef, Schmidt Enno, Jochum Wolfram, Mani Bernhard, Cozzio Antonio, Braun Anne, Emtenani Shirin, Hammers Christoph, Abdou Marie-Therese, Diem Stefan, Fässler Mirjam, Berner Fiamma, Ring Sandra S, Bomze David, Flatz Lukas
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer
Berner F, Hartmann F, Cheng H, Hönger G, Recher M, Goldman J, Cozzio A, Früh M, Neefjes J, Driessen C, Ludewig B, Hegazy A, Jochum W, Speiser D, Zippelius A, Läubli H, Bomze D, Diem S, Ali O, Fässler M, Ring S, Niederer R, Ackermann C, Baumgaertner P, Pikor N, Cruz C, van de Veen W, Akdis M, Nikolaev S, Flatz L. Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. JAMA Oncol 2019; 5:1043-1047.
Jul 1, 2019Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer
Jul 1, 2019JAMA Oncol 2019; 5:1043-1047
Berner Fiamma, Hartmann Fabienne, Cheng Hung-Wei, Hönger Gideon, Recher Mike, Goldman Jonathan, Cozzio Antonio, Früh Martin, Neefjes Jacques, Driessen Christoph, Ludewig Burkhard, Hegazy Ahmed N, Jochum Wolfram, Speiser Daniel E, Zippelius Alfred, Läubli Heinz, Bomze David, Diem Stefan, Ali Omar Hasan, Fässler Mirjam, Ring Sandra, Niederer Rebekka, Ackermann Christoph J, Baumgaertner Petra, Pikor Natalia, Cruz Cristina Gil, van de Veen Willem, Akdis Mübeccel, Nikolaev Sergey, Flatz Lukas
Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment
Diem S, Risch M, Recher M, Risch L, Dummer R, Levesque M, Mangana J, Hillmann D, Niederer R, Berner F, Ali O, Bomze D, Fässler M, Flatz L. Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. J Immunother 2019; 42:89-93.
Apr 1, 2019Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment
Apr 1, 2019J Immunother 2019; 42:89-93
Diem Stefan, Risch Martin, Recher Mike, Risch Lorenz, Dummer Reinhard, Levesque Mitchell P, Mangana Joanna, Hillmann Dorothea, Niederer Rebekka, Berner Fiamma, Ali Omar Hasan, Bomze David, Fässler Mirjam, Flatz Lukas
Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
Fässler M, Jörger M, Recher M, Risch L, Güsewell S, Risch M, Speiser D, Ludewig B, Levesque M, Dummer R, Siano M, Krolik M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Gil Cruz C, Pérez Shibayama C, Flatz L. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. J Immunother Cancer 2019; 7:50.
Feb 20, 2019Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
Feb 20, 2019J Immunother Cancer 2019; 7:50
Fässler Mirjam, Jörger Markus, Recher Mike, Risch Lorenz, Güsewell Sabine, Risch Martin, Speiser Daniel E, Ludewig Burkhard, Levesque Mitchell P, Dummer Reinhard, Siano Marco, Krolik Michal, Diem Stefan, Mangana Joanna, Hasan Ali Omar, Berner Fiamma, Bomze David, Ring Sandra, Niederer Rebekka, Gil Cruz Cristina, Pérez Shibayama Christian Ivan, Flatz Lukas
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
Hasan Ali O, Lenz T, Driessen C, Früh M, Jörger M, Cozzio A, Diem S, Fässler M, Bomze D, Berner F, Flatz L. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur J Cancer 2018; 107:8-14.
Dec 7, 2018Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
Dec 7, 2018Eur J Cancer 2018; 107:8-14
Hasan Ali Omar, Lenz Tobias L, Driessen Christoph, Früh Martin, Jörger Markus, Cozzio Antonio, Diem Stefan, Fässler Mirjam, Bomze David, Berner Fiamma, Flatz Lukas
Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment
Diem S, Früh M, Güsewell S, Schmid S, Ackermann C, Roux G, Berner F, Niederer R, Siano M, Ali O, Fässler M, Flatz L. Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment. Cancer Manag Res 2018; 10:5537-5544.
Nov 8, 2018Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment
Nov 8, 2018Cancer Manag Res 2018; 10:5537-5544
Diem Stefan, Früh Martin, Güsewell Sabine, Schmid Sabine, Ackermann Christoph Jakob, Roux Guillaume-Alexandre, Berner Fiamma, Niederer Rebekka, Siano Marco, Ali Omar Hasan, Fässler Mirjam, Flatz Lukas